Switch theme
Sign up to access all valuation multiples
Laboratorios Richmond SACIF is an Argentine pharmaceutical company that develops and manufactures quality pharmaceutical products. The products are offered to physicians, pharmacists, health institutions and patients. The product offered by the group include antiviral, oncologic and oncohematologic, cardiovascular, and neuropsychiatric products; and hospital products.
1959
n/a
Last FY Revenue $69.3M
Last FY EBITDA $29.5M
$118M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Laboratorios Richmond achieved revenue of $69.3M and an EBITDA of $29.5M.
Laboratorios Richmond expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Laboratorios Richmond valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $69.3M | XXX | XXX | XXX |
| Gross Profit | XXX | $37.8M | XXX | XXX | XXX |
| Gross Margin | XXX | 54% | XXX | XXX | XXX |
| EBITDA | XXX | $29.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 43% | XXX | XXX | XXX |
| EBIT | XXX | $11.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | 16% | XXX | XXX | XXX |
| Net Profit | XXX | $18.0M | XXX | XXX | XXX |
| Net Margin | XXX | 26% | XXX | XXX | XXX |
| Net Debt | XXX | $25.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Laboratorios Richmond's stock price is ARS 1280 (or $1).
Laboratorios Richmond has current market cap of ARS 103B (or $78.0M), and EV of ARS 156B (or $118M).
See Laboratorios Richmond trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $118M | $78.0M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Laboratorios Richmond has market cap of $78.0M and EV of $118M.
Laboratorios Richmond's trades at 1.7x EV/Revenue multiple, and 4.0x EV/EBITDA.
Equity research analysts estimate Laboratorios Richmond's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Laboratorios Richmond's P/E ratio is not available.
See valuation multiples for Laboratorios Richmond and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $78.0M | XXX | $78.0M | XXX | XXX | XXX |
| EV (current) | $118M | XXX | $118M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 10.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 4.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -48.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLaboratorios Richmond's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Laboratorios Richmond's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Laboratorios Richmond's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Laboratorios Richmond and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 43% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Laboratorios Richmond acquired XXX companies to date.
Last acquisition by Laboratorios Richmond was XXXXXXXX, XXXXX XXXXX XXXXXX . Laboratorios Richmond acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Laboratorios Richmond founded? | Laboratorios Richmond was founded in 1959. |
| Where is Laboratorios Richmond headquartered? | Laboratorios Richmond is headquartered in Argentina. |
| Is Laboratorios Richmond publicy listed? | Yes, Laboratorios Richmond is a public company listed on BUE. |
| What is the stock symbol of Laboratorios Richmond? | Laboratorios Richmond trades under RICH ticker. |
| When did Laboratorios Richmond go public? | Laboratorios Richmond went public in 2017. |
| Who are competitors of Laboratorios Richmond? | Similar companies to Laboratorios Richmond include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Laboratorios Richmond? | Laboratorios Richmond's current market cap is $78.0M |
| Is Laboratorios Richmond profitable? | Yes, Laboratorios Richmond is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
